Loading...
XETRAFX
Market cap4.16bUSD
Dec 20, Last price  
45.80EUR
1D
0.00%
1Q
-18.87%
Jan 2017
30.86%
Name

Carl Zeiss Meditec AG

Chart & Performance

D1W1MN
XETR:AFX chart
P/E
13.81
P/S
1.92
EPS
3.32
Div Yield, %
2.45%
Shrs. gr., 5y
—
Rev. gr., 5y
10.28%
Revenues
2.07b
-1.11%
00569,695,000600,190,000640,089,000676,682,000758,793,000861,875,000906,445,000909,255,0001,040,061,0001,088,365,0001,189,896,0001,280,860,0001,459,321,0001,335,452,0001,646,785,0001,902,836,0002,089,300,0002,066,127,000
Net income
179m
-38.45%
0047,757,00056,241,00055,101,00059,636,00072,274,00071,870,00093,505,00074,954,00062,297,00098,330,000134,445,000126,463,000159,756,000122,385,000236,276,000293,909,000290,396,000178,726,000
CFO
247m
-1.41%
45,831,00055,509,00056,079,00054,872,00087,356,00065,211,00037,545,00092,100,00064,624,00063,105,00056,744,000111,770,00037,732,000187,207,000219,634,000178,527,000362,663,000188,199,000250,861,000247,319,000
Dividend
Mar 22, 20241.1 EUR/sh
Earnings
Feb 07, 2025

Profile

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers products and solutions for the diagnosis and treatment of eye diseases; and systems and consumables for cataract, retinal, and refractive surgeries. It serves practicing ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The Microsurgery segment offers visualization solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, dental and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.
URL
https://www.zeiss.de/meditec-ag/
IPO date
Mar 20, 2000
Employees
4,224
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
2,066,127
-1.11%
2,089,300
9.80%
1,902,836
15.55%
Cost of revenue
1,889,794
1,736,870
1,504,663
Unusual Expense (Income)
NOPBT
176,333
352,430
398,173
NOPBT Margin
8.53%
16.87%
20.93%
Operating Taxes
60,712
120,555
107,578
Tax Rate
34.43%
34.21%
27.02%
NOPAT
115,621
231,875
290,595
Net income
178,726
-38.45%
290,396
-1.20%
293,909
24.39%
Dividends
(98,204)
(98,385)
(80,497)
Dividend yield
Proceeds from repurchase of equity
(150,075)
BB yield
Debt
Debt current
24,590
21,816
21,587
Long-term debt
278,104
289,576
234,219
Deferred revenue
Other long-term liabilities
502,647
129,456
124,715
Net debt
282,409
279,336
228,623
Cash flow
Cash from operating activities
247,319
250,861
188,199
CAPEX
(86,814)
(65,651)
(81,971)
Cash from investing activities
(412,305)
(110,980)
(148,894)
Cash from financing activities
176,249
(135,094)
(38,236)
FCF
793,228
21,749
155,412
Balance
Cash
20,285
10,601
7,729
Long term investments
21,455
19,454
Excess cash
Stockholders' equity
1,590,646
1,552,766
1,409,954
Invested Capital
2,710,473
2,458,055
2,258,995
ROIC
4.47%
9.83%
13.90%
ROCE
6.19%
14.14%
17.45%
EV
Common stock shares outstanding
89,735
89,441
89,441
Price
Market cap
EV
EBITDA
309,104
426,493
467,942
EV/EBITDA
Interest
29,424
15,250
9,593
Interest/NOPBT
16.69%
4.33%
2.41%